R97.0
Elevated carcinoembryonic antigen [CEA]
Clinical Classification Guidelines
Medical Intelligence & Overview
Elevated carcinoembryonic antigen (CEA) refers to higher-than-normal levels of a protein called CEA in the blood. CEA is a substance that can be produced by some cancer cells and, occasionally, by non-cancerous conditions. Monitoring CEA levels helps healthcare providers evaluate the presence or progression of certain cancers, especially colorectal, pancreatic, lung, breast, and other gastrointestinal cancers. An increase in CEA levels doesn’t always mean cancer is present, but it is an important marker used within broader diagnostic processes.
Causes & Symptoms
Clinical Causes: Presence of certain types of cancers, especially colorectal, lung, breast, pancreas, and gastrointestinal cancers Non-cancerous conditions such as inflammation of the pancreas, liver disease, or inflammatory bowel disease Smoking is known to slightly increase CEA levels Benign conditions like infections or benign tumors Following cancer treatments, elevated levels might indicate recurrence
Key Symptoms: Often no specific symptoms directly linked to high CEA levels If associated with cancer, typical symptoms may include unexplained weight loss, fatigue, and localized symptoms depending on the affected organ In cases of inflammation or infection, symptoms might include fever, pain, or swelling It is important to remember that elevated CEA alone does not cause symptoms but can be associated with underlying health issues
Diagnostic & Treatment
Diagnosis Path: Healthcare providers usually measure CEA levels through a simple blood test. When elevated CEA levels are detected, further investigations are typically recommended to identify the underlying cause. These may include imaging studies such as CT scans, MRI, or ultrasounds, along with other laboratory tests. The diagnosis process is comprehensive, aiming to determine whether cancer or another condition is responsible for the increased CEA.
Treatment Protocols: Treatment options depend on the underlying cause of the elevated CEA levels. If associated with cancer, management may include surgery, chemotherapy, radiation therapy, or targeted treatments, often combined with regular monitoring of CEA levels. For non-cancerous causes, treating the underlying condition—such as controlling inflammation or infections—can help normalize CEA levels. It’s essential for patients to work closely with their healthcare team to establish an appropriate management plan, tailored to their specific health needs.
Clinical Advice & FAQs
Billing Guidance
Is R97.0 a billable ICD-10 code?
Yes, R97.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report R97.0?
Clinical documentation must specify the nature of Elevated carcinoembryonic antigen [CEA] and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
